About ERADIVIR INC
Eradivir is a biotechnology company focused on developing antibody-recruiting small molecule therapies to treat diseases, including influenza and other viral infections. The company utilizes its Bispecific Antigenic immuno-Therapy (BAiT) platform to selectively target diseased cells and activate the immune system.
Development of antibody-recruiting small molecule therapiesUtilization of Bispecific Antigenic immuno-Therapy (BAiT) platformCreation of pharmaceuticals targeting viral infections and cancerPreclinical and clinical development of therapeutics, including EV25 for influenza
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| ERADIVIR INC. IND STUDIES IS TO COMPLETE A PACKAGE OF GLP-COMPLIANT NONCLINICAL SAFETY STUDIES THAT WILL SUPPO | Department of Health and Human Services | $749K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ERADIVIR INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.